Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Solid Tumors 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Trastuzumab 77Capecitabine 59Cyclophosphamide 54Paclitaxel 51Docetaxel 49Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 25exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Everolimus 17Taxes 16Epirubicin 15Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13pertuzumab 12palbociclib 12liposomal doxorubicin 11Magnetic Resonance Spectroscopy 11Filgrastim 11Cisplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × motesanib diphosphate × Clear all
NCT00356681 2015-10-15

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Amgen

Phase 2 Terminated
282 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡